SOLNA, Sweden--(BUSINESS WIRE)--Aerocrine AB (OMX Nordic Exchange: AERO) announces that a clinical trial published in The American Journal of Respiratory and Critical Care Medicine shows that FeNO-testing is an excellent tool to identify patients that don’t adhere to treatment.
The American Journal of Respiratory and Critical Care Medicine published on December 1, 2012, the results of a clinical study done at Queen’s University in Belfast, Northern Ireland. The results show how fractional exhaled nitric oxide (FeNO) measurement is an excellent tool for identifying patients who did not use their prescribed inhaled corticosteroids, i.e. did not adhere to treatment. Identifying non-adherence to medication is important because it allows improved patient characterization and tailoring of asthma management to individual needs, which, in turn, results in better patient outcomes at lower cost. Aerocrine’s patented FeNO test, with the NIOX MINO® device, was used in the study.
The UK study is entitled: The Utility of Fractional Exhaled Nitric Oxide Suppression in Identification of Nonadherence in Difficult Asthma; its purpose was to identify a test for non-adherence using fractional exhaled nitric oxide (FeNO) suppression after directly observed inhaled corticosteroid treatment. The study concluded that the FeNO suppression test can identify whether or not patients use their inhaled corticosteroid therapy properly and if patients, who fill their prescriptions, took their medicine. Non-adherence is common and ranges from 35–65%.
An editorial in the same journal stated that there are studies which suggest that FeNO measurements may be used to confirm non-adherence with inhaled corticosteroid therapy in children. But no study has yet investigated the same measurements in adults. The editorial concludes that “the strength of the study justify the introduction of this test in clinical practice”.
Asthma is a chronic inflammatory airways disease that is characterized by symptoms including wheezing and difficulty in breathing. Asthma is one of the world’s most common and costly diseases; it affects 8–10% of the population and is associated with enormous healthcare expenditures that include direct and indirect costs. The disease has no cure, and proper diagnosis and management are crucial for improved quality of life for the patients. FeNO measurement enables physicians to better assess and manage patients with allergic airway inflammation.
References: McNicholl, D.M., M. Stevenson, L.P. McGarvey, and L.G. Heaney, “The Utility of Fractional Exhaled Nitric Oxide Suppression in the Identification of Nonadherence in Difficult Asthma”. American Journal of Respiratory and Critical Care Medicine, 2012. 186(11): p. 1102-1108. (http://ajrccm.atsjournals.org/content/186/11/1102.abstract) http://ajrccm.atsjournals.org/content/186/11/1102.abstract
Bel, E.H., “Measuring adherence to inhaled corticosteroids in asthma: getting closer!” Am J Respir Crit Care Med, 2012. 186(11): p. 1067-8.
Aerocrine AB is a medical products company focused on improved management and care of patients with inflammatory airway diseases such as Asthma. Within this sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO®, which enables fast and reliable point-of-care measurement of airway inflammation. This product plays a critical role in more effective diagnosis, treatment and follow-up of patients affected with inflammatory airway diseases. Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland and the UK. Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007 (AERO-B.ST). For more information please visit www.aerocrine.com and www.niox.com.
This information was brought to you by Cision http://www.cisionwire.com